Idelalisib+Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma
Status:
Active, not recruiting
Trial end date:
2023-04-06
Target enrollment:
Participant gender:
Summary
Single arm, prospective, multi-centric, phase II study. Patients with histologically
confirmed follicular lymphoma, in need of a systemic approach and failing (i.e. with
refractory disease [no response or response lasting less than 6 months at any previous line
of treatment] or with a proven disease relapse) at least 2 previous lines of treatment,
including any antibody directed against the CD20 antigen-containing chemotherapy, will
undergo a combined chemo-free treatment with obinutuzumab and idelalisib.